Avalo Therapeutics, Inc. (NASDAQ:AVTX) Shares Acquired by Affinity Asset Advisors LLC

Affinity Asset Advisors LLC raised its stake in Avalo Therapeutics, Inc. (NASDAQ:AVTX) by 1,123.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 550,765 shares of the company’s stock after purchasing an additional 505,765 shares during the quarter. Affinity Asset Advisors LLC owned about 0.05% of Avalo Therapeutics worth $4,092,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently modified their holdings of AVTX. Geode Capital Management LLC lifted its position in Avalo Therapeutics by 937.0% during the 4th quarter. Geode Capital Management LLC now owns 104,853 shares of the company’s stock worth $779,000 after acquiring an additional 94,742 shares in the last quarter. Bank of Montreal Can acquired a new stake in Avalo Therapeutics in the fourth quarter valued at approximately $446,000. Finally, Walleye Capital LLC purchased a new stake in shares of Avalo Therapeutics during the fourth quarter valued at approximately $145,000. Hedge funds and other institutional investors own 87.06% of the company’s stock.

Avalo Therapeutics Trading Up 9.8 %

Shares of NASDAQ AVTX opened at $5.38 on Tuesday. The business has a 50 day simple moving average of $7.17 and a 200-day simple moving average of $8.83. Avalo Therapeutics, Inc. has a twelve month low of $4.44 and a twelve month high of $18.79.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the stock. Stifel Nicolaus assumed coverage on shares of Avalo Therapeutics in a report on Tuesday, March 25th. They set a “buy” rating and a $36.00 price target for the company. Piper Sandler started coverage on Avalo Therapeutics in a research note on Friday, February 28th. They set an “overweight” rating and a $48.00 price objective for the company. BTIG Research began coverage on Avalo Therapeutics in a research report on Thursday, December 19th. They issued a “buy” rating and a $40.00 target price on the stock. Wedbush reissued an “outperform” rating and set a $18.00 price target on shares of Avalo Therapeutics in a research report on Thursday, March 20th. Finally, HC Wainwright restated a “neutral” rating on shares of Avalo Therapeutics in a research note on Thursday, March 20th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $33.00.

Avalo Therapeutics Company Profile

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.